# Catalyst Calendar (2026-01-30 UTC)

Rows: 10

## 2026-02-15

- **PVLA** | **NDA_BLA_SUBMISSION** (approx) | D-16 | conf 0.75 | filing_txt:EX-99.1
  - token: Q1 2026
  - context: stic Lymphatic Malformations Annual ~$100k-$200k pricing range per patient supported by payor research and analogue orphan launches (e.g., Oxervate, Arikayce, Tepezza) 1. Incidence, prevalence, and care for patients with lymphatic malformations (LMs) in the U.…
- **PVLA** | **TOPLINE** (approx) | D-16 | conf 0.70 | filing_txt:EX-99.1
  - token: Q1 2026
  - context: ers, if any, to these trademarks, service marks, trade names and copyrights. PALVELLA (pɑlʋelːɑ, Finnish): TO SERVE Building the leading rare disease biopharma company focused on developing and commercializing first-in-disease therapies for serious, rare skin …

## 2026-07-11

- **CORT** | **PDUFA** | D-162 | conf 0.85 | filing_txt:EX-99.1
  - context: patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The ROSELLA tr…

## 2026-07-20

- **KALA** | **TOPLINE** | D-171 | conf 0.65 | filing_txt:8-K
  - context: false 0001479419 0001479419 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securit…

## 2026-11-14

- **SMMT** | **PDUFA** | D-288 | conf 0.85 | filing_txt:EX-99.1
  - context: a2026_prx0129xfdablaacce 1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on…
- **SMMT** | **PDUFA** | D-288 | conf 0.80 | filing_txt:EX-99.1
  - context: a2026_prx0129xfdablaacce 1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on…
- **SMMT** | **FILING_ACCEPTANCE** | D-288 | conf 0.80 | filing_txt:EX-99.1
  - context: a2026_prx0129xfdablaacce 1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on…
- **SMMT** | **FILING_ACCEPTANCE** | D-288 | conf 0.75 | filing_txt:EX-99.1
  - context: a2026_prx0129xfdablaacce 1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on…
- **SMMT** | **NDA_BLA_SUBMISSION** | D-288 | conf 0.75 | filing_txt:EX-99.1
  - context: a2026_prx0129xfdablaacce 1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on…

## 2026-11-15

- **TVRD** | **TOPLINE** (approx) | D-289 | conf 0.70 | filing_txt:EX-99.1
  - token: Q4 2026
  - context: on to have dual therapeutic effect on cancer cells – overcoming tumorigenesis and immune suppression Clinically meaningful activity in both monotherapy and combination therapy in areas of unmet need Topline results from ongoing Phase 2 REVERTLIVER CANCER trial…
